Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
Home Editorial Board Current Issue Special Issue Archives Indexing Submit Article
Instruction to Authors Manuscript Charges Copyright Form Model Manuscript Process Flow (Time Frame) FAQ
Reviewer Guidelines Selection of Reviewers Join our Team of Reviewers Apply as Reviewer Reviewer Login
Editorial Review Policy Embargo Policy Ethical Expectations Consent For Identifying Information Informed Consent Manuscript Withdrawal Policy Peer Review Process Plagiarism Policy Ethical Violations Appeal Policy Against Editorial Decision Advertising Policies Authorship Policy
Access Policies Authorship Publication Policy Publication Ethics Complaints Policy Confidential Information Conflicts of Interest Policy Consent for Copyrighted Material Copyright Policy Corrections and Retractions Digital Preservation Policy Research On Human And Animal Studies Open Access Policy
Publication Ethics Contact
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2023 - IJCMAS--ICV 2023: 95.56 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Join as a Reviewer

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here
ICV 2023: 95.56
Index Copernicus ICI Journals Master List 2023 - IJCMAS--ICV 2023: 95.56
For more details click here
Announcement

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles Volume : 14, Issue : 6, June, 2025

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com
submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38
Metrics and citations

Int.J.Curr.Microbiol.App.Sci.2025.14(6) : 109-117
DOI : https://doi.org/10.20546/ijcmas.2025.1406.010


Application of mRNA Vaccine Platforms for Emerging Infectious Diseases: Progress and Challenges

Densingh Johnrose1*, Mihir Sharma2, Azaarudin Gohil3 and Shivam Singh2
1Department of Microbiology and Immunology, Shree Dhanvantary International School, Kim,
Gujarat, India
2M.Pharm, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India
3Department of Biotechnology, Shree Dhanvantary International School, Kim, Gujarat, India
*Corresponding author
Abstract:

Emerging infectious diseases (EIDs) such as COVID-19, Zika, Ebola, and others pose a significant global health threat due to their rapid transmission and high morbidity. Traditional vaccine development methods are often too slow to respond effectively to new outbreaks. mRNA vaccine platforms have recently emerged as a transformative technology, offering rapid, scalable, and adaptable solutions for pandemic preparedness and response. This review aims to evaluate the progress of mRNA vaccine platforms in addressing emerging infectious diseases, examine their underlying mechanisms, highlight key successes, and discuss the challenges that remain for broad global implementation. A comprehensive literature review was conducted using databases including PubMed, Scopus, and Web of Science. Peer-reviewed articles, clinical trial results, and regulatory reports published between 2010 and 2025 were analyzed to assess the development, efficacy, and deployment of mRNA vaccines for EIDs. The success of mRNA vaccines against SARS-CoV-2 has validated their potential as a rapid-response platform. Preclinical and early clinical studies show promising results for other pathogens such as Zika virus, influenza, and Ebola. Advantages of mRNA platforms include rapid design, high potency, and reduced risk of insertional mutagenesis. However, challenges such as cold-chain storage requirements, limited data on long-term immunity, and manufacturing scalability remain significant barriers, especially in low- and middle-income countries. mRNA vaccines represent a critical advancement in the fight against EIDs, offering a flexible and accelerated pathway for vaccine development. Future efforts should focus on improving delivery systems, enhancing thermal stability, and building global infrastructure for equitable access. Continued research and international collaboration will be essential to fully harness the potential of mRNA vaccine technology for future public health emergencies.


Keywords: mRNA vaccines, emerging infectious diseases, vaccine platform, pandemic preparedness, immunogenicity, delivery systems, cold chain logistics

References:

 

 

  1. Kim, J.; Eygeris, Y.; Gupta, M.; Sahay, G. Self-assembled mRNA vaccines. Drug Deliv. Rev. 2021, 170, 83–112.

  2. Maruggi, G.; Zhang, C.; Li, J.; Ulmer, J.B.; Yu, D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Ther. 2019, 27, 757–772.

  3. Fang, E.; Liu, X.; Li, M.; Zhang, Z.; Song, L.; Zhu, B.; Wu, X.; Liu, J.; Zhao, D.; Li, Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 2022, 7, 94.

  4. Firdessa-Fite, R.; Creusot, R.J. Nanoparticles versus dendritic cells as vehicles to deliver mRNA encoding multiple epitopes for immunotherapy. Ther. Methods Clin. Dev. 2020, 16, 50–62.

  5. Xu, S.; Yang, K.; Li, R.; Zhang, L. Mrna vaccine era—Mechanisms, drug platform and clinical prospection. J. Mol. Sci. 2020, 21, 6582.

  6. Cagigi, A.; Loré, K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines 2021, 9, 61.

  7. Pascolo, S. Vaccination with Messenger RNA (mRNA). In Toll-Like Receptors (TLRs) and Innate Immunity; Springer: Berlin/Heidelberg, Germany, 2008; pp. 221–235.

  8. Khalid, K.; Padda, J.; Khedr, A.; Ismail, D.; Zubair, U.; Al-Ewaidat, O.A.; Padda, S.; Cooper, A.C.; Jean-Charles, G. HIV and Messenger RNA (mRNA) Vaccine. Cureus 2021, 13, e16197. [Google Scholar]

  9. Rogers, J. NIH Launches Clinical Trial of Three mRNA HIV Vaccines [Internet]. National Institutes of Health (NIH). 2022.

  10. Tabak, L. Encouraging First-in-Human Results for a Promising HIV Vaccine [Internet]. NIH Director’s Blog. 2023.

  11. Essink, B.; Chu, L.; Seger, W.; Barranco, E.; Le Cam, N.; Bennett, H.; Faughnan, V.; Pajon, R.; Paila, Y.D.; Bollman, B.; et al., The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect. Dis. 2023, 23, 621–633.

  12. Zhu, Y.; Zhu, L.; Wang, X.; Jin, H. RNA-based therapeutics: An overview and prospectus. Cell Death Dis. 2022, 13, 644.

  13. Sahin, U.; Oehm, P.; Derhovanessian, E.; Jabulowsky, R.A.; Vormehr, M.; Gold, M.; Maurus, D.; Schwarck-Kokarakis, D.; Kuhn, A.N.; Omokoko, T.; et al., An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020, 585, 107–112.

  14. Khattak, A.; Weber, J.S.; Meniawy, T.; Taylor, M.H.; Ansstas, G.; Kim, K.B.; McKean, M.; Long, G.V.; Sullivan, R.J.; Faries, M.B.; et al., Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. Clin. Oncol. 2023, 41 (Suppl. 17), LBA9503–3.

  15. Rojas, L.A.; Sethna, Z.; Soares, K.C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; et al., Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023, 618, 144–150.

  16. Jin, L.; Han, Z.; Zhao, P.; Sun, K. Perspectives and Prospects on mRNA Vaccine Development for COVID-19. Med. Chem. 2022, 29, 3991.

  17. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age—Full Text View—ClinicalTrials.gov.

  18. Chakraborty, C.; Sharma, A.R.; Bhattacharya, M.; Lee, S.-S. From COVID-19 to Cancer mRNA Vaccines: Moving from Bench to Clinic in the Vaccine Landscape. Immunol. 2021, 12, 679344.

  19. Park, J.W.; Lagniton, P.N.P.; Liu, Y.; Xu, R.H. mRNA vaccines for COVID-19: What, why and how. J. Biol. Sci. 2021, 17, 1446.

  20. Wilson, E.; Goswami, J.; Baqui, A.H.; Doreski, P.A.; Perez-Marc, G.; Zaman, K.; ConquerRSV Study Group. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. Engl. J. Med. 2023, 389, 2233–2244.

  21. Amanpour, S. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Razi Inst. 2021, 76, 1.

  22. Provine, N.M.; Klenerman, P. Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity. J. Immunol. 2022, 53, 2250022.

  23. Zhang, H.; Zhang, L.; Lin, A.; Xu, C.; Li, Z.; Liu, K.; Liu, B.; Ma, X.; Zhao, F.; Jiang, H.; et al., Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity. Nature 2023, 621, 396–403.

  24. Brito, L.A.; Chan, M.; Shaw, C.A.; Hekele, A.; Carsillo, T.; Schaefer, M.; Archer, J.; Seubert, A.; Otten, G.R.; Beard, C.W.; et al., A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Ther. 2014, 22, 2118–2129.

  25. Démoulins, T.; Milona, P.; Englezou, P.C.; Ebensen, T.; Schulze, K.; Suter, R.; Pichon, C.; Midoux, P.; Guzmán, C.A.; Ruggli, N.; et al., Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine 2016, 12, 711–722.

  26. Kim, S.C.; Sekhon, S.S.; Shin, W.-R.; Ahn, G.; Cho, B.-K.; Ahn, J.-Y.; Kim, Y.-H. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Cell. Toxicol. 2022, 18, 1–8.

  27. Gote, V.; Bolla, P.K.; Kommineni, N.; Butreddy, A.; Nukala, P.K.; Palakurthi, S.S.; Khan, W. A Comprehensive Review of mRNA Vaccines. J. Mol. Sci. 2023, 24, 2700.

  28. Granados-Riveron, J.T.; Aquino-Jarquin, G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Pharmacother. 2021, 142, 111953.

  29. Kowalski, P.S.; Rudra, A.; Miao, L.; Anderson, D.G. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Ther. 2019, 27, 710–728. [Google Scholar] [CrossRef]

  30. Pollard, C.; De Koker, S.; Saelens, X.; Vanham, G.; Grooten, J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol. Med. 2013, 19, 705–713. [Google Scholar] [CrossRef]

  31. Weng, Y.; Huang, Y. Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins. Asian J. Pharm. Sci. 2021, 16, 263–264.

  32. Li, M.; Wang, Z.; Xie, C.; Xia, X. Advances in mRNA vaccines. Rev. Cell Mol. Biol. 2022, 372, 295–316.

  33. Yang, L.; Tang, L.; Zhang, M.; Liu, C. Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. Immunol. 2022, 13, 896958.

  34. da Silva, M.K.; Campos, D.M.O.; Akash, S.; Akter, S.; Yee, L.C.; Fulco, U.L.; Oliveira, J.I.N. Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools. Viruses 2023, 15, 2130.

  35. Lorentzen, C.L.; Haanen, J.B.; Met, O.; Svane, I.M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022, 23, e450–e458.

  36. Szabo, G.T.; Mahiny, A.J.; Vlatkovic, I. COVID-19 mRNA vaccines: Platforms and current developments. Ther. 2022, 30, 1850–1868.

  37. Chaudhary, N.; Weissman, D.; Whitehead, K.A. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Rev. Drug Discov. 2021, 20, 817–838.

  38. Ura, T.; Yamashita, A.; Mizuki, N.; Okuda, K.; Shimada, M. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine 2021, 39, 197. [Google Scholar] [CrossRef]

  39. Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. Rev. Drug Discov. 2018, 17, 261–279.

  40. Guevara, M.L.; Persano, S.; Persano, F. RNA therapeutics: Advances and challenges in the development of nucleic acid drugs. AAPS PharmSciTech 2022, 23, 51.

  41. Li, Y.; Zhang, S. Overcoming the stability challenge of mRNA vaccines. Drug Discov. Today 2022, 27, 1260–1267.

  42. Loomis, K.H.; Pradhan, S.; Mitragotri, S. Challenges and opportunities in mRNA vaccine delivery. Control. Release 2022, 345, 183–201.

  43. Feng, J.; Hu, Y.; Zhang, Y. Rational design of modified nucleosides for enhancing mRNA stability. Opin. Chem. Biol. 2023, 66, 29–37.

  44. Kaczmarek, J.C.; Patel, A.K.; Kauffman, K.J.; Fenton, O.S.; Webber, M.J.; Anderson, D.G. Development and clinical translation of approved mRNA vaccines. Opin. Biotechnol. 2022, 73, 252–261.

  45. Vogel, A.B.; Sterzynska, K. Towards stable and efficient mRNA vaccines—Successes and challenges. Vaccines 2022, 10, 92. [Google Scholar]

  46. Riedmann, E.M.; Cooney, C.L. Stability challenges and formulation strategies for RNA therapeutics. AAPS PharmSciTech 2022, 23, 57. [Google Scholar]

  47. Reichmuth, A.M.; Oberli, M.A.; Jaklenec, A.; Langer, R.; Blankschtein, D. mRNA vaccine delivery using lipids with innate immune-activating potential. Nano Lett. 2022, 22, 91–99.

  48. Chen, Q.; Peng, Z.; Zhang, Y. Strategies to improve the stability of mRNA vaccines: From formulation design to delivery systems. Drug Deliv. Rev. 2022, 189, 114427. Liu, T.; Liang, Y.; Huang, L. Development and Delivery Systems of mRNA Vaccines. Front. Bioeng. Biotechnol. 2021, 9, 718753.

Download this article as Download

How to cite this article:

Densingh Johnrose, Mihir Sharma, Azaarudin Gohil and Shivam Singh. 2025. Application of mRNA Vaccine Platforms for Emerging Infectious Diseases: Progress and Challenges. Int.J.Curr.Microbiol.App.Sci. 14(6): 109-117 doi: https://doi.org/10.20546/ijcmas.2025.1406.010
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license

Citations

Home | Terms of Use | Copyright Form 2012-2026 Copy rights reserved IJCMAS. Powered by ThinkNEXT Technologies
"; var printWin = window.open( '', '', 'scrollbars=yes,width=' + w + ',height=' + h + ',top=' + top + ',left=' + left ); printWin.document.write(html); printWin.document.close(); printWin.focus(); printWin.print(); printWin.close(); }